Sclerotherapy for lower limb telangiectasias.

Area of Science:

• Vascular Medicine
• Dermatology
• Medical Interventions

Background:

• Sclerotherapy has a long history in clinical practice for treating vascular conditions.
• Despite its use, there is no established consensus on the most effective sclerosing agent for optimal patient outcomes.

Purpose of the Study:

• To evaluate the effectiveness and safety of various sclerosing agents for treating lower limb telangiectasias.
• To compare different sclerosing agents against each other and against placebo treatments.

Main Methods:

• A systematic review of randomized and quasi-randomized controlled trials was conducted.
• Studies compared sclerotherapy agents to normal saline placebo, no treatment, or alternative sclerotherapy regimens.
• Data extraction and risk of bias assessment were performed by two authors.

Main Results:

• Sclerotherapy demonstrated superiority over normal saline placebo in treating telangiectasias.
• No significant difference in efficacy or patient satisfaction was found between different sclerosing agents.
• Polidocanol (1%) and sodium tetradecyl sulfate (1%) were associated with more adverse reactions compared to lower concentrations or other agents.
• Sodium tetradecyl sulfate was reported as more painful than polidocanol, heparsal, or placebo.

Conclusions:

• Current evidence suggests sclerotherapy is more effective than placebo for leg telangiectasias, but no single agent is definitively superior.
• The available research is limited in quantity and quality, hindering definitive conclusions on optimal agent selection and dosing.
• Further high-quality research is required to identify the best sclerosing agents and dosages for maximizing efficacy and patient satisfaction.